Merck BioVentures: where biosimilars make a difference
This article was originally published in Scrip
Executive Summary
Mike Kamarck, the president of Merck BioVentures, tells ScripIntelligence Managing Editor, John Hodgson, how pharma companies are shaping the biosimilars rules in the US, why Merck switched from biobetters to biosimilars, and why Enbrel is a good place to start a biosimilars business.